Clinical Trials
26 trialsNCT05902169 2026-06-05
SONOBIRD
CarThera
Phase 3 Recruiting
NCT04164199 2026-06-03
Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies
BeOne Medicines
Phase 3 Completed
NCT06743126 2026-05-29
SUPRAME
Immatics US, Inc.
Phase 3 Recruiting
NCT07195591 2026-05-29
BRIDGES
GT Medical Technologies, Inc.
Phase 3 Recruiting
NCT06556563 2026-05-01
EF-41
NovoCure Ltd.
Phase 3 Recruiting
NCT06346067 2026-02-27
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)
Erasca, Inc.
Phase 3 Active not recruiting
NCT04919226 2025-09-10
COMPOSE
ITM Solucin GmbH
Phase 3 Active not recruiting
NCT02667587 2025-06-18
CheckMate548
Bristol-Myers Squibb
Phase 3 Completed
NCT03776071 2024-04-22
A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1
Denovo Biopharma LLC
Phase 3 Completed
NCT02573324 2023-05-11
Intellance1
AbbVie
Phase 3 Completed
NCT03495921 2023-04-26
VITA
Gradalis, Inc.
Phase 3 Terminated
NCT02617589 2023-03-28
CheckMate 498
Bristol-Myers Squibb
Phase 3 Completed
NCT05647954 2022-12-13
A Study of HX008 Plus Transcatheter Arterial Chemoembolization (TACE) in the First-Line Treatment of Subjects With Stage IV (M1c) Melanoma That is Metastatic to the Liver
Taizhou Hanzhong biomedical co. LTD
Phase 3 Unknown
NCT02288897 2022-01-19
PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma
Provectus Pharmaceuticals
Phase 3 Terminated
NCT03419403 2021-04-14
UNITE Study: Understanding New Interventions With GBM ThErapy
AbbVie
Phase 3 Terminated
NCT01480479 2018-01-16
ACT IV
Celldex Therapeutics
Phase 3 Completed
NCT00943826 2017-09-25
A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma
Hoffmann-La Roche
Phase 3 Completed
NCT00091572 2017-06-06
Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma (Study P03267)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT00335075 2017-05-15
Efficacy and Safety of Temodal vs Semustine in Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma (Study P03644)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT00916409 2017-04-10
Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM)
NovoCure Ltd.
Phase 3 Completed
NCT00761280 2014-11-14
SAPPHIRE
Isarna Therapeutics GmbH
Phase 3 Terminated
NCT00689221 2014-11-04
CENTRIC
EMD Serono
Phase 3 Completed
NCT00395070 2013-09-13
A Phase 3 Pivotal Trial Comparing Allovectin-7® Alone vs Chemotherapy Alone in Patients With Stage 3 or Stage 4 Melanoma
Vical
Phase 3 Completed
NCT00257205 2012-07-02
CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy
AstraZeneca
Phase 3 Completed
NCT00615186 2011-02-10
Glass-Art
Bradmer Pharmaceuticals Inc.
Phase 3 Terminated
NCT00068952 2008-04-01
Study of IV Edotecarin Vs Temozolomide or Carmustine (BCNU) or Lomustine (CCNU) in Patients With Glioblastoma Multiforme
Pfizer
Phase 3 Completed